
A clever(t) fusion for prostate diagnosis
Statistically speaking every fourth older German man suffers from prostate cancer with the mortality rate being 60,000 patients annually
Statistically speaking every fourth older German man suffers from prostate cancer with the mortality rate being 60,000 patients annually
Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is sending a promising duo into the race against cancer: A new PET/MR system that can combine high-resolution images with functional information to improve cancer diagnosis.
The German Cancer Research Center (DKFZ) and Bayer HealthCare (Bayer) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy.
EKF Diagnostics, worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays, has announced the launch of a new division to focus on molecular and companion diagnostics.
‘All human body cells contain the same DNA, but every type of cell – for example a muscle cell compared to that of a nerve – has a different gene expression pattern’, said Dr Sonja Stadler, speaking at the 2012 congress of DGKL (German Society for Clinical Chemistry).
The international research project ‘The Definition of new types of tumours containing potential mutations sensitivity to drugs’ has begun in Petrov Research Institute of Oncology in St Petersburg, the oldest Russian oncology institute.
In a Special Focus Session, experts addressed the necessity to perform palliative interventional techniques in cancer treatment and they insisted that interventional radiologists should become more than just technicians.
Modern imaging techniques greatly enhance the treatment selection
Hedvig Hricak, Chair of the Radiology Department at the Memorial Sloan-Kettering Cancer Center, New York, USA, describes emerging applications and potential trends in gynaecological cancer treatment described at the 15th International Symposium Crossing Barriers
CT scanners now nicely cover morphology. The challenge is moving to CT functional imaging without frying patients
The hepatocellular carcinoma is the sixth most frequent cause of cancer worldwide, explained Dr Bruno Sangro at ECR, and it is the third most frequent cause of death due to cancer.
You won't find a single new machine among the novel technology shaping radiology. Instead software, not hardware, is the key that is opening new frontiers.
Experts across Europe believe the combination is beginning to demonstrate its broad potential as a hybrid imaging tool
The last decade saw PET and now PET/CT numbers expand rapidly in Europe. More recently the picture has been less rosy with public and private sectors delaying new projects and pushing back the replacement of equipment.
Simultaneous surgical successes open new perspectives for multiple transplants
Colon cancer remains the second most common cause of cancer-related death in the Western world with 450,000 citizens in Europe newly diagnosed and 230,000 deaths annually (Source: Globalscan 2008).
Forty years ago an article was published that would change medical practice. In the British Journal of Radiology, English electrical engineer Godfrey N Hounsfield described how he had made a patient’s brain visible non-invasively by evaluating a large number of X-ray images of the skull taken from different directions.
In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.
‘We aim to develop an understanding of which novel research activities could bring benefits for patients,’ explained Professor Christof von Kalle, Director of the Department of Translational Oncology, NCT (German National Centre for Tumour Diseases) and the German Cancer Research Centre (DKFZ), speaking on translational activities during the New Cancer Targets gathering in Heidelberg this…
‘The disease “cancer” is increasingly classified into sub-groups. Today, we are already dealing with a number of orphan diseases,’ says Professor Richard Greil MD, head of LIMCR at University Hospital Salzburg.
A dynamic new consortium was launched in October during the recent Innovation in Oncology event organised by the German Cancer Research Centre (DKFZ) with Heidelberg University Hospital.
BRAF is a protein that plays an important part in the transmission of growth signals. In a mutated state it can lead to uncontrolled cell growth. Around every second malignant melanoma – the deadliest and most aggressive form of skin cancer – has a certain mutation of the BRAF gene.
French and German experts hear of a possible new computer-based system to identify new biomarkers for colon cancer.
Individually customised drug therapies have been used for the last two years, particularly for cancer patients